BioMarin Pharmaceutical | BMRN - Equity Capital And Reserves

Stock Price
57.82
Daily Change
0.20 0.34%
Monthly
-3.75%
Yearly
-10.14%
Q1 Forecast
54.80

BioMarin Pharmaceutical reported $6.06B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.28B 85.22M Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Amgen USD 9.62B 2.19B Sep/2025
Bayer EUR 29.7B 799M Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Gilead Sciences USD 21.46B 1.78B Sep/2025
Incyte USD 4.65B 480.29M Sep/2025
Insmed USD 945.57M 304.16M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Moderna USD 9.33B 69M Sep/2025
Neurocrine Biosciences USD 3B 309.3M Sep/2025
PTC Therapeutics USD -155.76M 50.79M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 71.71B 14.25B Dec/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
United Therapeutics USD 6.59B 583.4M Sep/2025
Vertex Pharmaceuticals USD 17.32B 143.4M Sep/2025